Vanqua Bio to Speak at First GBA1 2024 Meeting

Vanqua Bio, a Chicago-based biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, announced its participation in the first-ever GBA1 meeting. This event, set to take place from June 27-29, 2024, at The Montreal Neurological Institute-Hospital, will gather health professionals and stakeholders from academia and industry who are engaged in GBA1 research. The meeting is supported by several notable organizations, including Cure Parkinson’s, The Michael J. Fox Foundation, Parkinson Canada, The Silverstein Foundation, and the Hilary & Galen Weston Foundation.

The primary objective of the GBA1 meeting is to enhance the collective understanding and treatment of GBA1-related neurodegenerative diseases. Discussions will span various aspects of GBA1 research, ranging from fundamental science to clinical trials. This event will serve as a valuable platform for professionals to network, learn, and collaborate.

Vanqua Bio will present a poster at the meeting, showcasing their research on a promising treatment for GBA-Parkinson’s Disease. The presentation, titled "VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase, Demonstrates Neuroprotection in Models of GBA-Parkinson’s Disease and Robust in Vivo Target Engagement," will be delivered by Daniel Ysselstein on June 29th at 12:20 PM ET.

Vanqua Bio, established in 2019, is dedicated to discovering and developing next-generation medicines aimed at transforming the lives of patients suffering from neurodegenerative diseases. The company's technology platform leverages human genetics and patient-derived neuronal cells to identify, validate, and translate novel disease pathways associated with lysosomal dysfunction or abnormal activation of the innate immune system into clinical treatments. Initially, their research is focused on targeting glucocerebrosidase (GCase) as a potential treatment for Parkinson’s disease. Additionally, Vanqua Bio is exploring therapies for other neurodegenerative disorders linked to excessive activation of the innate immune system, such as Alzheimer’s disease.

Vanqua Bio continues to advance its mission of developing transformative therapies for neurodegenerative diseases, building on its innovative approach and commitment to scientific excellence.